FierceBiotech ١٣ أبريل ٢٠٢٦ BioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor types
FierceBiotech ٢٨ فبراير ٢٠٢٦ BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival